# Modelling cost-effectivenss for LAAB-PrEP vs. shielding 
Modelling for cost effectiveness of shielding and LAAB for immunocompromised people
## Cost effectivness based on sensitivity analysis

## Association analysis
## Senario analysis

## Individual risk group analysis
Ref: https://www.thelancet.com/journals/lanepe/article/PIIS2666-7762(23)00166-7/fulltext#tbl2
